Theoretical and experimental substantiation of receiving a pharmaceutical composition in the form of a cryogel with lidocain hydrochloride and decametoxin

А. М. Соломенний, А. О. Дроздова
{"title":"Theoretical and experimental substantiation of receiving a pharmaceutical composition in the form of a cryogel with lidocain hydrochloride and decametoxin","authors":"А. М. Соломенний, А. О. Дроздова","doi":"10.32352/0367-3057.1.23.07","DOIUrl":null,"url":null,"abstract":"Modern medicines for the treatment of wounds are developed on the basis of knowledge about their phase healing. The main principle of wound treatment is the creation and maintenance of a moist environment, stable temperature, absorption of excess exudate, minimization of the risk of sensitization, increased intervals between dressings, easy removal of coatings from the surface of the wound. The implementation of this principle is the basis of our research on the creation of a cryogel – a supermacroporous hydrogel that is formed at subzero temperatures by polymerization of monomers or cryogel formation of oligomers without the use of toxic organic solvents and with controlled textural and structural characteristics. A comprehensive study of cryogels has like theoretical as practical interest, because they can serve as a perspectiving new material in pharmacy for obtaining new medicines. \nThe purpose of our research was to substantiate the composition of the cryogel with lidocaine hydrochloride and decamethoxine based on the conducted pharmacotechnological, physicochemical and biopharmaceutical research methods. Model samples (№№ 1–10) with different contents of lidocaine hydrochloride, decamethoxine, and auxiliary substances were selected as research objects. Pharmacotechnological, physicochemical and biopharmaceutical research methods were used. \nThe technological and biopharmaceutical factors of development pharmaceutical composition in the form of a cryogel with lidocaine hydrochloride and decamethoxine were studied. Based on the results of the research, we found that samples (№№ 1–10) are homogeneous without signs of delamination, no changes are observed (aggregation of particles, sediment, odor). Samples №№ 3, 9 and 10 differ in the presence/absence of API. It was shown that APIs do not affect the absorption capacity of the studied samples. Comparative studies confirm our assumption that the presence of PG in the cryogel increases the absorption of liquid by the samples. The prolongation of the action in the composition depends on the presence of PG in the sample of composition. The prolonged effect of pharmaceutical composition was established. For further research, sample № 10 (lidocaine hydrochloride – 0.4; decamethoxine – 0.03; PVA 15% – 20.0; PG – 10.0) was chosen.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmatsevtichnii zhurnal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32352/0367-3057.1.23.07","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Modern medicines for the treatment of wounds are developed on the basis of knowledge about their phase healing. The main principle of wound treatment is the creation and maintenance of a moist environment, stable temperature, absorption of excess exudate, minimization of the risk of sensitization, increased intervals between dressings, easy removal of coatings from the surface of the wound. The implementation of this principle is the basis of our research on the creation of a cryogel – a supermacroporous hydrogel that is formed at subzero temperatures by polymerization of monomers or cryogel formation of oligomers without the use of toxic organic solvents and with controlled textural and structural characteristics. A comprehensive study of cryogels has like theoretical as practical interest, because they can serve as a perspectiving new material in pharmacy for obtaining new medicines. The purpose of our research was to substantiate the composition of the cryogel with lidocaine hydrochloride and decamethoxine based on the conducted pharmacotechnological, physicochemical and biopharmaceutical research methods. Model samples (№№ 1–10) with different contents of lidocaine hydrochloride, decamethoxine, and auxiliary substances were selected as research objects. Pharmacotechnological, physicochemical and biopharmaceutical research methods were used. The technological and biopharmaceutical factors of development pharmaceutical composition in the form of a cryogel with lidocaine hydrochloride and decamethoxine were studied. Based on the results of the research, we found that samples (№№ 1–10) are homogeneous without signs of delamination, no changes are observed (aggregation of particles, sediment, odor). Samples №№ 3, 9 and 10 differ in the presence/absence of API. It was shown that APIs do not affect the absorption capacity of the studied samples. Comparative studies confirm our assumption that the presence of PG in the cryogel increases the absorption of liquid by the samples. The prolongation of the action in the composition depends on the presence of PG in the sample of composition. The prolonged effect of pharmaceutical composition was established. For further research, sample № 10 (lidocaine hydrochloride – 0.4; decamethoxine – 0.03; PVA 15% – 20.0; PG – 10.0) was chosen.
接受冷冻凝胶形式的药物组合物与盐酸利多卡因和地高辛的理论和实验证实
治疗伤口的现代药物是在了解伤口的阶段愈合的基础上发展起来的。伤口处理的主要原则是创造和维持一个潮湿的环境,稳定的温度,吸收多余的渗出液,最大限度地减少致敏的风险,增加敷料之间的间隔,容易从伤口表面去除涂层。这一原理的实现是我们研究创造低温凝胶的基础——一种在零下温度下通过单体聚合或低聚物低温凝胶形成的超大孔水凝胶,不使用有毒有机溶剂,具有可控的结构和结构特征。对低温材料的全面研究不仅具有理论意义,而且具有实践意义,因为它可以作为药学研究中获得新药的新材料。本研究的目的是通过药理学、理化和生物制药等方面的研究方法,确定盐酸利多卡因和十甲基托辛冷冻凝胶的组成。选取盐酸利多卡因、十甲基托辛及辅助物质含量不同的模型样品(№1-10)作为研究对象。采用了药物技术、物理化学和生物制药等研究方法。研究了以盐酸利多卡因和十甲基托辛为低温凝胶开发药物组合物的工艺和生物制药因素。根据研究结果,我们发现样品(№№1-10)是均匀的,没有分层的迹象,没有观察到变化(颗粒聚集,沉积物,气味)。样品№3,9和10在存在/不存在API方面有所不同。结果表明,原料药不影响样品的吸收能力。比较研究证实了我们的假设,即PG在低温凝胶中的存在增加了样品对液体的吸收。在组合物中作用的延长取决于组合物样品中PG的存在。确定了药物组合物的长效作用。为进一步研究,样品№10(盐酸利多卡因- 0.4;十甲氧辛- 0.03;Pva 15% - 20.0;PG - 10.0)被选中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
43
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书